Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9552W HIGH $6.40
Volume
35.37 K
Value Traded
32.83 K
Short % Float
2.67%
+3.67%Week
-17.52%1 Month
-15.67%3 Month
-42.64%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.70 M
EPS (TTM)
-33.32
P/E Ratio
-
Ent. Value
-19.09 M
Total Shares
4.16 M
Float Shares
4.01 M
Insiders
6.99%
Institutions
2.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NCNA Catalyst Timeline
Dated clinical, regulatory and corporate events for NuCana plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for NuCana plc
188Total events
2Upcoming
36Tier-1 (high impact)
2017 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedNUC-7738IP / Competition
EPO grants composition-of-matter patent EP 3683225 for NUC-7738
◆Poster PresentationNUC-7738Presentation
Poster presentation of Phase 2 expansion study of NUC-7738 in combination with pembrolizumab at ESMO IO 2025
PD-1 inhibitor-resistant cutaneous melanomasource ↗
◆Enrollment UpdateNUC-7738Trial
Enrollment update: 9 patients treated in Expansion Cohort, planned enrollment up to 28 additional patients
PD-1 inhibitor-resistant cutaneous melanomasource ↗
▲Oral PresentationNUC-7738Presentation
Compelling data from Phase 2 NuTide:701 study presented at ESMO Immuno-Oncology Congress
PD-1 inhibitor-resistant metastatic melanomasource ↗
▲Patent GrantedNUC-7738IP / Competition
Composition-of-matter patent granted for NUC-7738 in China
cancersource ↗
▲Poster PresentationNUC-7738Presentation
Poster presentation at ESMO 2025 on NUC-7738 synergy with PD-1 inhibitors in patient-derived organoids
renal cell carcinomasource ↗
▲Enrollment UpdateNUC-7738Trial
Regulatory approval to expand NuTide:701 study to recruit additional 28 patients with PD-1 inhibitor-resistant melanoma
melanomasource ↗
▲Full ResultsNUC-3373+ leucovorinClinical Data
Publication of NuTide:303 clinical data on medRxiv and preclinical data in PLOS ONE
advanced solid tumorssource ↗
◆AbstractNUC-7738Presentation
Abstract on NUC-7738 synergy with PD-1 inhibition published online
Renal Cell Cancersource ↗
▼Reverse Stock SplitCorporate
ADS ratio change from 1:25 to 1:5000 (effective 1-for-200 reverse ADS split)
▲ATM ProgramCorporate
Cancellation of all outstanding Series A Warrants following ATM execution
◆Trial InitiationNUC-7738Trial
Initiate expansion study of NUC-7738 in combination with pembrolizumab
PD-1 inhibitor-resistant melanomasource ↗
◆FDA Feedback ReceivedNUC-7738FDA Meeting
FDA meeting to seek guidance on registration strategy for NUC-7738
PD-1 inhibitor-resistant melanomasource ↗
◆Topline ReadoutNUC-7738Clinical Data
Data from NuTide:701 expansion study expected later in 2025
PD-1 inhibitor-resistant melanomasource ↗
◆Topline ReadoutNUC-3373+ leucovorinClinical Data
Data from NuTide:303 study of NUC-3373 in combination with pembrolizumab or docetaxel
advanced solid tumorssource ↗
▲Full ResultsNUC-3373+ leucovorinClinical Data
Initial data from Phase 1b/2 modular study of NUC-3373 in combination with pembrolizumab or docetaxel published in MedRxiv
advanced solid tumorssource ↗
▼Enrollment PausedNUC-3373+ leucovorinTrial
Enrollment in Module 2 (NUC-3373 + docetaxel) put on hold due to toxicity challenges
lung cancer (NSCLC, pleural mesothelioma)source ↗
▲Patent GrantedNUC-7738IP / Competition
USPTO grants composition-of-matter patent US12,054,510 for NUC-7738
▲Oral PresentationNUC-7738Presentation
Final data from Phase 2 NuTide:701 study of NUC-7738 plus pembrolizumab presented at ESMO Congress 2024
metastatic melanomasource ↗
▲Full ResultsNUC-7738Clinical Data
Final data from Phase 2 NuTide:701 study of NUC-7738 plus pembrolizumab
metastatic melanomasource ↗
▲Oral PresentationNUC-7738Presentation
Encouraging data presented at ESMO Congress 2024 for NUC-7738 plus pembrolizumab
PD-1 inhibitor resistant melanomasource ↗
▼Trial DiscontinuedNUC-3373+ leucovorinTrial
NuTide:323 study discontinued following pre-planned initial analysis
colorectal cancersource ↗
◆Reverse Stock SplitCorporate
ADS ratio change (1:25 reverse ADS split) to regain Nasdaq compliance
▲Poster PresentationNUC-7738Presentation
Poster presentation on lipidome reprogramming by NUC-7738 in combination with anti-PD-1 therapy at AACR 2024
cutaneous melanomasource ↗
▲Enrollment CompleteNUC-3373+ leucovorinTrial
Randomized Phase 2 study of NUC-3373 fully recruited 171 patients
second-line advanced colorectal cancersource ↗
▲Patent GrantedNUC-7738IP / Competition
USPTO granted composition of matter patent for NUC-7738
◆Topline ReadoutNUC-3373+ leucovorinClinical Data
Data from Phase 1b/2 study of NUC-3373 + pembrolizumab and NUC-3373 + docetaxel expected in 2024
solid tumors and lung cancersource ↗
◆Topline ReadoutNUC-7738Clinical Data
Additional updates from Phase 2 part of NUC-7738 + pembrolizumab study expected in 2024
melanomasource ↗
◆Poster PresentationNUC-3373+ leucovorinPresentation
Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab or docetaxel
advanced solid tumors; lung cancersource ↗
◆Poster PresentationNUC-7738Presentation
NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results
metastatic melanomasource ↗
▲Oral PresentationNUC-3373+ leucovorinPresentation
Data presented from NuTide:302 study in second-line CRC patients at AACR-NCI-EORTC 2023
colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How NCNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-31 | Acelarin combined with cisplatin | Phase 3 interim results | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$3M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
0.8x
rNPV / MCap
Top 81%
Micro Cap(rank 533 of 658)
Percentile Rank
NuCana plc faces pipeline headwinds (26/100), with $272M risk-adjusted pipeline value, led by NUC-3373+ leucovorin in Colorectal Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NUC-3373+ leucovorin Small moleculeCompletedNCT03428958 | Colorectal Cancer | Phase 1 | COMPLETED | 111 | Mar 21, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every NCNA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NUC-7738 | PD-1 inhibitor-resistant melanoma | Phase 2 | 2026-03-19 | two partial responses; one of which was confirmed; multiple cases of stable disease; one patient whose disease converted to a complete metabolic response with no detectable active diseaseRead More | NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data frRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bruce Theresa Margaret MsOfficer (Chief Operating Officer) | Grant/Award | 132,600,130 132,600,130 held | $0.00 | 04/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NCNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0 % (-100 %) | 884.00 K | 3.40 M | -27.4% ( -1.28 M) |
NCNA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NCNA ranks across every disease it competes in
Competitive Position is a premium feature
See how NCNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNCNA News
NCNA▲ +11.6%on this news
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
NuCana plc announced the European Patent Office granted a composition-of-matter patent for NUC-7738, enhancing its global patent protection strategy. This patent is crucial as NUC-7738 is currently in the Phase 2 part of a clinical study for treating PD-1 inhibitor-resistant metastatic melanoma. The company is optimistic about its future operations and clinical advancements.
Read more →NCNA▲ +7.4%on this news
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
NuCana plc reported its second quarter 2026 financial results, highlighting that the final data from the Phase 2 expansion study of NUC-7738 is on schedule for release in 2026. The company also announced plans to advance additional indications and combination strategies for NUC-7738. Furthermore, NuCana's cash runway is projected to last until 2029.
Read more →NCNA▼ -6.9%on this news
NuCana Appoints Ian Webster as Chief Financial Officer
NuCana plc has appointed Ian Webster as Chief Financial Officer, effective immediately. Webster, who has been with the company since 2019, previously served as Interim CFO. His extensive experience in finance, particularly in the biopharmaceutical sector, positions him well to guide NuCana's financial strategy as the company advances its clinical pipeline, including the Phase 2 study of NUC-7738.
Read more →NCNA▲ +5.9%on this news· ran to +17% by day 1
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
NuCana plc reported its first quarter 2026 financial results, highlighting progress in its clinical development, particularly for NUC-7738, which has received FDA IND clearance. The company aims to advance its Phase 2 expansion study for NUC-7738 in melanoma and is exploring additional indications. Despite a net loss for the quarter, NuCana's cash resources are expected to support operations through 2029.
Read more →NCNA▲ +5.9%on this news· ran to +17% by day 1
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, Notes 2026 2025 (in thousands, except per share data) Research and development expenses (3,213 ) (1,725 ) Administ
NuCana PLC released its unaudited consolidated financial results for the three months ended March 31, 2026. The report indicates a substantial increase in both operating losses and overall loss compared to the previous year, with operating loss rising to $4.42 million and total comprehensive loss increasing to $3.85 million. Research and development expenses have notably surged, rising from $1.73 million to $3.21 million. The company's losses reflect ongoing financial challenges as it continues to develop cancer treatments using its proprietary ProTide technology.
Read more →NCNAA New Era in Oncology Notice of 2026 Annual General Meeting Monday, 8th June 2026 at 11.00am Venue: Lochside House 3 Lochside Way Edinburgh EH12 9DT U.K. NuCana plc 77-78 Cannon Street, London, England, EC4N 6AF Company
NuCana plc is set to hold its 2026 Annual General Meeting on June 8, 2026, at Lochside House, Edinburgh. The notice outlines various resolutions including the re-election of directors and the reappointment of auditors. The Company’s board emphasizes that passing these proposals is essential for maintaining its financial plans. Shareholders are encouraged to vote in advance by appointing the Chair as their proxy.
Read more →NCNANuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NuCana plc (NASDAQ: NCNA) announced its fourth quarter and year-end 2025 financial results, highlighting the promising clinical activity of NUC-7738 in treating PD-1 inhibitor-resistant melanoma. The Phase 2 NuTide:701 study has shown efficacy, including partial responses and stable disease in patients. The company also reported a net loss of $2.5 million for Q4 2025, though it is optimistic about its cash resources extending into 2029. Future plans include completing enrollment in the expansion study and seeking regulatory guidance on possible approval pathways.
Read more →NCNANuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana plc has appointed Theresa Bruce as its new Chief Operating Officer, effective January 1, 2026. Bruce brings over 25 years of experience in oncology research and development, which NuCana anticipates will bolster its operational leadership. The company is focused on advancing its pipeline, particularly the Phase 1/2 study of NUC-7738, aimed at improving cancer treatment outcomes. NuCana expects to benefit from several data readouts in 2026, enhancing its market position in cancer therapies.
Read more →NCNANuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana plc presented promising clinical data for NUC-7738 at the ESMO Immuno-Oncology Congress 2025. The treatment demonstrated clinical activity in patients with PD-1 inhibitor-resistant metastatic melanoma, including confirmed partial responses and stable disease. No new safety signals were observed, reinforcing the treatment's favorable safety profile. The findings support ongoing patient enrollment in the trial, aimed at exploring the potential benefits of NUC-7738 further.
Read more →NCNANuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana plc reported its third quarter 2025 financial results, highlighting encouraging data for its lead anti-cancer drugs, NUC-7738 and NUC-3373. The company is well-capitalized with a cash runway extending into 2029 and is actively recruiting patients for ongoing clinical studies. Initial data from the expansion study of NUC-7738 is expected in Q4 2025, with final data anticipated in 2026.
Read more →NCNA▼ -7.9%on this news
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended September 30, For the Nine Months Ended September 30, Notes 2025 2024 2025 2024 (in thousands, except per share data) Resear
NuCana PLC reported its unaudited condensed consolidated financial performance for the three and nine months ending September 30, 2025, indicating a notable operating loss of $15.5 million. The results show a decrease in research and development expenditures, which is a positive sign. However, the company is still facing substantial cumulative losses and challenges related to cash flow management. They reported a modest increase in cash reserves, but ongoing financial uncertainty remains a key concern as they continue their biopharmaceutical developments.
Read more →NCNANuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana plc has received a composition-of-matter patent for NUC-7738 from the China National Intellectual Property Administration. This patent will bolster the company's worldwide patent strategy, aiding the ongoing Phase 1/2 clinical study involving NUC-7738 in patients with PD-1 inhibitor refractory melanoma. The CEO highlighted the encouraging clinical data supporting the drug's potential in cancer treatment. NuCana continues to advance its novel ProTide technology aimed at enhancing chemotherapy efficacy.
Read more →NCNANuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor- Infiltrating Lymphocytes at the ESMO Congress 2025 NUC-7738 Synergizes with P
NuCana announced promising data at the ESMO Congress 2025 regarding NUC-7738, particularly its synergy with PD-1 inhibitors in treating renal cell carcinoma. The data, derived from co-cultured patient-derived organoids, indicates that NUC-7738 could enhance the effectiveness of existing PD-1 therapies. The ongoing NuTide:701 study has shown a favorable safety profile and meaningful tumor reduction in melanoma patients unresponsive to PD-1 treatment. NuCana plans to expand patient recruitment and has received approval from regulators for this initiative.
Read more →NCNANuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients
NuCana plc announced promising data regarding their drug NUC-3373 in combination with pembrolizumab for patients with advanced solid tumors. The latest update reveals a patient with melanoma has remained progression-free for 23 months following treatment. Preclinical data further supports the drug's safety and efficacy, indicating potential advancements in treatment outcomes for cancer patients. The company is also exploring further clinical studies to optimize combination regimens.
Read more →NCNANuCana Compliant with All Nasdaq Continued Listing Criteria Anticipated Cash Runway into 2029
NuCana plc has confirmed compliance with all Nasdaq continued listing criteria, closing a previous listing matter. The company expects its cash resources to sustain operations and support key milestones through 2029. Additionally, NuCana's pipeline includes promising anti-cancer agents such as NUC-7738 and NUC-3373, with multiple upcoming data readouts that could enhance treatment outcomes for patients with cancer. The positive developments position NuCana favorably for future advancements in cancer therapy.
Read more →NCNANuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
NuCana plc announced that it will present data on NUC-7738's synergy with PD-1 inhibitors at the ESMO Congress 2025 in Berlin. The presentation, titled 'Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer,' is scheduled for October 19, 2025. NUC-7738 is being evaluated as a potential treatment for advanced solid tumors either as a monotherapy or in combination with pembrolizumab. NuCana's ProTide technology aims to enhance the efficacy of existing chemotherapy agents.
Read more →NCNA▼ -12.6%on this news
NUCANA PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended June 30, For the Six Months Ended June 30, Notes 2025 2024 2025 2024 (in thousands, except per share data) Research and deve
NuCana plc has released its unaudited condensed consolidated statements of operations for the six months ended June 30, 2025, depicting significant financial challenges. The company reported an operating loss of 24,442, larger than the previous year, driven by increased research and administrative expenses. A substantial net loss of 26,587 was recorded for the period, raising concerns about financial sustainability as the accumulated deficit reached 250,696. The report underscores ongoing hurdles as NuCana progresses in its development of innovative cancer therapies.
Read more →NCNA▼ -8.9%on this news
NuCana Announces ADS Ratio Change
NuCana plc announced its decision to change the ratio of its American Depository Shares (ADSs) effective August 11, 2025. The new ratio will be one ADS representing five thousand ordinary shares, which effectively acts as a one-for-two hundred reverse split. This adjustment aims to bolster the liquidity of NuCana's ADSs and assist in aligning with Nasdaq's minimum bid price requirement. Registered holders must surrender their certificated ADSs, but those using the Direct Registration System will undergo an automatic exchange.
Read more →NCNA▲ +6.9%on this news
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
NuCana plc has successfully canceled all outstanding Series A Warrants after raising the necessary capital through its at-the-market offering. This cancellation, completed as of July 21, 2025, eliminates the overhanging rights from earlier offerings and represents a key strategic move for the company. NuCana is focused on enhancing treatment outcomes in cancer patients with its proprietary ProTide technology, and continues to advance its promising drug candidates NUC-7738 and NUC-3373 in clinical trials.
Read more →NCNA▼ -15.9%on this news
NuCana Announces Plan to Implement ADS Ratio Change
NuCana plc announced a plan to change the ratio of its American Depository Shares (ADSs), effective August 8, 2025. The new ratio will be one ADS representing 5,000 ordinary shares, akin to a one-for-two hundred reverse ADS split. This move is designed to enhance liquidity and regain compliance with Nasdaq's minimum bid price requirement. While the change could positively influence the trading price of the ADSs, there are no guarantees regarding its effectiveness.
Read more →About NuCana plc
BIOPHARMAWATCH ELITE PLUS
Trade the next NCNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime